摘要
Among the gynecological cancers, ovarian cancer is the most lethal. Its therapeutic options include a combination of chemotherapy with platinum-based compounds and cytoreductive surgery. Most ovarian cancer patients exhibit an initial response to platinum-based therapy, however, platinum resistance has led to up to 80% of this responsive cohort becoming refractory. Ovarian cancer recurrence and drug resistance to current chemotherapeutic options is a global challenge. Chemo-resistance is a complex phenomenon that involves multiple genes and signal transduction pathways. Therefore, it is important to elucidate on the underlying molecular mechanisms involved in chemo-resistance. This inform decisions regarding therapeutic management and help in the identification of novel and effective drug targets. Studies have documented the individual biomarkers of platinum-resistance in ovarian cancer that are potential therapeutic targets. This review summarizes the molecular mechanisms of platinum resistance in ovarian cancer, novel drug targets, and clinical outcomes.
学科与关键词
- A Novel Platinum Resistance-Related Immune Gene Signature for Overall Survival Prediction in Patients with Ovarian CancerZhou, Chenfei; Ma, Junnan; Luo, Wanjun; Hu, Jiemei; Chen, Jing; Liang, Suiying; He, Shanyang*Biochemical Genetics, 2024, 62(1): 112-124.
- Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profilingC Zeller; W Dai; N L Steele; A Siddiq; A J Walley; C S M Wilhelm-Benartzi; S Rizzo; A van der Zee; J A Plumb; R BrownOncogene, 2012, 31(Suppl 2).
- Is Autophagy Always a Barrier to Cisplatin Therapy?Xu, Jingwen; Gewirtz, David A.*Biomolecules, 2022, 12(3): 463.被引 21
